Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Comparison of CM310 (Stapokibart) in Healthy Subjects
NCT05702450Phase 1Completed
- Sponsor
- Keymed Biosciences
- Start
- Mar 2023
- Primary completion
- Jul 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of stapokibart in atopic dermatitis (AD), chronic rhinosinusitis with nasal polyps (CRSwNP) and asthma (2 arms), sponsored by Keymed Biosciences. Primary endpoint: Maximum Concentration up to 57 days. Started Mar 2023; status: completed.
02
Drugs
stapokibart
03
Conditions
atopic dermatitis (AD)chronic rhinosinusitis with nasal polyps (CRSwNP)asthma
Beyond the preview
Go deeper on NCT05702450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05702450.